Login / Register

Username:


Password: [Lost?]



New User? Click here for your FREE subscription



Healthcare Professionals
Healthcare Professionals Healthcare Professionals

Follow Us


NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest


Healthcare Conferences &
Educational Opportunities








Ongoing

Skin, Bones, Hearts & Private Parts - CME NOW OnDemand

Skin, Bones, Hearts & Private Parts

Dec. 5 - 05, 2023

SkinBonesCME NOW - On-demand

Skin, Bones, Hearts & Private Parts

May 1, 2023 - 04, 2023

Skin, Bones, Hearts & Private Parts - Savannah, Ga

Skin, Bones, Hearts & Private Parts

June 13, 2023 - 16, 2023

Skin, Bones, Hearts & Private Parts - Destin, Fl

Skin, Bones, Hearts & Private Parts

June 26, 2023 - 29, 2023

Skin, Bones, Hearts & Private Parts - Myrtle Beach, Sc

Skin, Bones, Hearts & Private Parts

More Events

NIH DREAM Study Finds Viagra and Cialis Do Not Reduce Risk of Alzheimer’s and Related Dementias | NEWS-Line for Mental Health Professionals
 


NIH DREAM Study Finds Viagra and Cialis Do Not Reduce Risk of Alzheimer’s and Related Dementias


Source:

Results from the National Institutes of Health’s Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study show that sildenafil (Viagra) and tadalafil (Cialis) may not be suitable candidates for treating dementia. These findings are contrary to similar, previously reported research from another group. In this new study, NIH researchers and collaborators used data from Medicare beneficiaries and determined the medications sildenafil and tadalafil do not reduce the risk of Alzheimer’s disease and related dementias. The study was funded by the NIH National Institute on Aging (NIA) and results published in Brain Communications. Identifying existing drugs that may also be repurposed for dementia could potentially get treatments to those in need faster than the traditional drug discovery process.

The NIA scientific team tested a class of drugs called phosphodiesterase-5 (PDE5) inhibitors. PDE5 inhibitors, of which sildenafil and tadalafil are examples, work by relaxing smooth muscle cells. Sildenafil and tadalafil are U.S. Food and Drug Administration-approved treatments for erectile dysfunction and pulmonary atrial hypertension (PAH), a type of high blood pressure that affects the arteries in the lungs and the right side of the heart.

The scientists examined the risk of Alzheimer’s and related dementias using two groups of Medicare beneficiaries with PAH, those who were being treated with sildenafil or tadalafil, and those treated with another class of drugs. They also tested whether sildenafil had effects on cell culture-based models of Alzheimer’s. Results showed no reduced risk of Alzheimer’s and related dementias in patients treated with PDE5 inhibitors and no evidence that PDE5 inhibitors corrected molecular abnormalities associated with Alzheimer’s.

The research is part of the DREAM initiative led by Madhav Thambisetty, M.D., Ph.D., chief of the NIA Clinical and Translational Neuroscience Section (CTNS). The DREAM collaborative, which includes researchers from NIA, Harvard Medical School, Boston; Rutgers University, New Brunswick; and the Johns Hopkins School of Medicine, Baltimore; is a multidisciplinary initiative to identify candidate treatments for Alzheimer’s and related dementias by repurposing drugs that are FDA-approved for other indications.

Previous results from the DREAM study showed some arthritis drugs may reduce Alzheimer’s and related dementias risk in those with heart disease.

This research is related to NIA’s AD+ADRD Milestone 7.B, “Initiate research programs for translational bioinformatics and network pharmacology to support rational drug repositioning and combination therapy from discovery through clinical development.”

Reference

Desai RJ, et al. No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer’s disease and related dementia: results from the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study. Brain Commun. 2022; doi: https://doi.org/10.1093/braincomms/fcac247(link is external)

About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related cognitive change and neurodegenerative diseases via NIA’s Alzheimer's and related Dementias Education and Referral (ADEAR) Center website. Visit the main NIA website for information about a range of aging topics, in English and Spanish, and stay connected.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov..

NIH…Turning Discovery Into Health®

Source: National Institute on Aging (NIA)





Post not cached because it doesn't exist


Share This!


Healthcare Jobs




Director of Surgical Services

Finley Hospital
Dubuque, IA

Medical Director, Student Health Services

Old Dominion University
Norfolk, VA

Psych Rehab Spec I - Psych Rehab Spec TR I - Art Therapist

LOUISVILLE, KY

Clinical Nursing Residential Faculty

GateWay Community College
Phoenix, AZ

Faculty - Health Professions - Evening Nursing Program

Reading Area Community College
Reading, PA

Sonographers, MRI Tech & CT Tech

Anderson Healthcare
Maryville & Staunton, Illinois

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.